N/A
Completed N=70
The Effect of Riboflavin in Crohn's Disease
Crohn Disease
Source: ClinicalTrials.gov NCT02538354 ↗
Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcomePrimary: F. Prausnitzii (FISH Analysis). — 4.53; 5.07; 6.19; 5.46 Relative FISH counts from total bacteria
Summary
This study will evaluate if suppelementation of the diet with riboflavin in Crohn's disease patients will result in an increase in the amount of F. prausnitzii.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY F. Prausnitzii (FISH Analysis). |
4.53; 5.07; 6.19; 5.46 | — |
Eligibility Criteria
Inclusion Criteria
- Crohn's disease patients
- Age 18-65 years
- Concomitant medication for Crohn's disease is allowed in all groups
Exclusion Criteria
- Swallowing disorders
- Pregnancy and lactation
- Use of antibiotic drugs, probiotics (i.e.Yakult, Vifit, Activia etc) or specific prebiotic supplements in the 3 weeks prior to the riboflavin intervention
- Use of Methotrexate drugs
- Colonoscopy and colon cleansing in last 3 months
- Use of a vitamin B2 supplement, or multivitamin complexes containing vitamin B (i.e. vitamin B-complex) in the 3 weeks prior to the riboflavin intervention
- Severe Crohn's disease (HBI > 12)
Data sourced from ClinicalTrials.gov (NCT02538354). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.